MedX Has a Broad International Portfolio of Granted Patents (17) and Many Patents Pending (23)
Patented Technology Applicable In Burn and Wound Care Markets
MISSISSAUGA, ON, April 19, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy and light imaging systems, announced that MedX Health Corporation has been granted two (2) new patents, expanding the broad International portfolio to seventeen (17) granted patents, with another twenty-three (23) patents pending. US patent #8,145,294 and Australian patent #2006220441 are Image Processing Method and Apparatus patents. Both patents focus on the use of light to capture images within the skin from a distance using a digital camera or similar device. The technology is called 'non-contact' siascopy. In contrast, 'contact siascopy,' which is used in the current MedX Health skin cancer imaging patented product, MoleMate, creates images of structures under the skin while resting lightly on the skin, via an 'optical biopsy.'
The non-contact patented technology allows a device to gather information on large sections of skin to analyze the surface and 2mm below the surface providing information on the general health of the skin, or a dermatological condition, or the extent of damage to the skin. This technology will be important in the future for evaluating burn patients to quickly determine if they need a skin graft or if less costly dressings are the best course of treatment. Additionally the non-contact version of this technology will be used to evaluate wounds to determine if they are healing properly and responding to the prescribed treatment.
"At MedX Health we believe that intellectual property, especially patents, represent an opportunity to derive new sources of revenues and profits and we will continue to seek out partners and the resources to help us capitalize on these opportunities," said Steve Guillen, President & CEO.
Burn and Wound Assessment Imaging
The worldwide advanced wound care market (burns, diabetic foot ulcers and bed sores) is estimated at $5 Billion (Global Industry Analysts, Inc.) and the market potential using the MedX platform technology may be worth hundreds of millions of dollars.
Proctor & Gamble, LenioMed Ltd., and ScreenCancer, Inc., are research and commercial partners that are funding the expansion of the underlying technology, into new consumer and wound care markets.
About MedX Health Corp.
MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. MedX Health acquired the worldwide assets of MoleMate, for early detection of skin cancer, in June, 2011. For a complete profile of MoleMate and the core technologies visit www.simsys-molemate.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information:
President and Chief Executive Officer
MedX Health Corp. [email protected]
Phone: (905) 670-4428